Dr. Oz's Push to Expand Medicare CBD Access After European Regulators Could Not Establish Safety of Charlotte's Web Hemp Extract

MMJ International Holdings’ CEO Duane Boise warns that Medicare patients should not be used as a testing ground for cannabinoid products that have not completed the FDA drug-development process. The statement emphasizes the need for evidence on safety, efficacy, manufacturing consistency, and appropriate dosing. No figures or policy changes were provided, so near-term market impact is likely limited.

Analysis

MMJ International Holdings’ CEO Duane Boise warns that Medicare patients should not be used as a testing ground for cannabinoid products that have not completed the FDA drug-development process. The statement emphasizes the need for evidence on safety, efficacy, manufacturing consistency, and appropriate dosing. No figures or policy changes were provided, so near-term market impact is likely limited.